F05 demonstrates additive anti-tumor effects in combination with mAb therapy and reprograms M2 macrophages towards a phagocytotic phenotype. by Keifer G. Kurtz (21416918)

“…CD163 MFI is significantly decreased with F05 treatment (p = 0.0089, 55% decrease), but not 1H9 (p = 0.0828, 31% decrease) when compared to RITUX.…”

Histological appearance of NT2 CisR xenograft tumors without (A) and with (B) DNase treatment, and quantification of intratumoral microvascular density (C). by Mego Michal (22783828)

Expression of ‘muscle’ genes in the tendon during early postnatal development. by Heather L. Dingwall (14573796)

Identification of VHL as a novel E3 ubiquitin ligase for Vpx. by Kei Miyakawa (255697)

“…Data are presented as mean ± standard deviation (SD) (n = 2). Statistical significance was evaluated using a two-tailed unpaired <i>t</i>-test. …”

Percentages of pediatricians and obstetricians/gynecologists working long hours, based on the desired working environment. by Mai Nakagawa (20284927)

Related to Fig 2. by Mohammad Nafees Ansari (22232505)

“…(<b>C</b>) Cell proliferation studies show a decrease in the proliferation of BT-474_RICTOR^SH cells (mean ± SEM, <i>n</i> = 3) compared to BT-474_SCRAM^SH cells. …”

Average wellness for matchday, MD by Ivan Baptista (5278874)

“…<div><p>Background</p><p>Exposure to match loads significantly affects physiological and psychological indicators and, consequently, players’ wellness. …”

RICTOR silencing inhibits cell proliferation via UGCG regulation. by Mohammad Nafees Ansari (22232505)

“…(<b>C</b>) Cell proliferation studies show a decrease in the proliferation of MCF-7_RICTOR^SH cells (mean ± SEM, <i>n</i> = 4) compared to MCF-7_SCRAM^SH cells. …”

The RehaGait® system. by Johanna Rydja (12300797)

“…</p><p>Trial registration</p><p>ClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT04795089" target="_blank">NCT04795089</a></p></div>…”

Flow chart of included patients and dropouts. by Johanna Rydja (12300797)

“…</p><p>Trial registration</p><p>ClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT04795089" target="_blank">NCT04795089</a></p></div>…”

Dataset of the analyzed data. by Johanna Rydja (12300797)

“…</p><p>Trial registration</p><p>ClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT04795089" target="_blank">NCT04795089</a></p></div>…”

<i>DQ6</i> protection as a function of iKIR score. by Laura Mora-Bitria (20477525)

ERI Thresholds Between Adjacent Zones. by Mingyue Sun (4638535)

“…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”

Location of the study area. by Mingyue Sun (4638535)

“…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”

Random Forest structure with cross-validation. by Mingyue Sun (4638535)

“…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”

Land use change from 1990 to 2020. by Mingyue Sun (4638535)

“…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”

Geographic data. by Mingyue Sun (4638535)

“…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”

Classification accuracy. by Mingyue Sun (4638535)

“…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”

Related to Fig 3. by Mohammad Nafees Ansari (22232505)

“…(<b>Q</b>) Tumor growth kinetics recorded a significantly higher growth of BT-474_ZFX^OE (mean ± SEM, <i>n</i> = 5) than BT-474_VECT^OE tumors. …”

Appearance and body color of <i>N</i>. <i>davidi</i> var. red. by Wei-Wei Hou (3405947)